ReviewJournal of Cancer2025
S-palmitoylation: a novel insight in the development and immunotherapy of oral squamous cell carcinoma.
Review in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S-palmitoylation (hereinafter referred to as palmitoylation) is a reversible lipid modification that has recently received considerable attention in cancer research. Despite its known association with tumour progression and treatment response, it remains unclear how palmitoylation could be targeted for enhancing therapeutic outcomes in oral squamous cell carcinoma (OSCC). This review summarises palmitoylated proteins common in various cancers and highlights emerging targets specific to OSCC, emphasising their roles in protein stability, signalling pathways, and cellular behaviour. Additionally, we explore new trends in targeting palmitoylated proteins to manage cancer progression and bolster the immune response in OSCC. Furthermore, this review highlights existing knowledge gaps and calls for detailed investigations into OSCC-specific palmitoylation mechanisms, including the expression levels of palmitoylated proteins and palmitoylation enzymes and their effect on OSCC signalling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.